
## Tandem Diabetes Care (Mon, Apr 22, 2024)

Buy candidate since Apr 22, 2024



StockInvest.us Gyneju st. 14, "ROCKIT" Vilnius, LT-01109 Lithuania

score: **2.42** 

#2272/30110

Trend:	Buy
MV Long:	Buy
MV Short:	Sel
Pivot:	Sel
Volume:	Buy
MACD:	Sel

## **Tech commentaries:**

The **Tandem Diabetes Care** stock price gained **4.27**% on the last trading day (Monday, 22nd Apr 2024), rising from **\$30.43** to **\$31.73**. During the last trading day the stock fluctuated **5.98**% from a day low at **\$30.12** to a day high of **\$31.92**. The price has fallen in 7 of the last 10 days and is down by **-5.42**% for this period. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, **19 thousand** more shares were traded than the day before. In total, **1** million shares were bought and sold for approximately **\$31.85** million.

The stock lies in the lower part of a very wide and strong rising trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at \$30.64 is broken, it will firstly indicate a slower rate of rising, but may also be an early warning for a trend shift. Given the current short-term trend, the stock is expected to rise **50.91%** during the next 3 months and, with a 90% probability hold a price between **\$46.24** and **\$58.53** at the end of this 3-month period.

The **Tandem Diabetes Care** stock holds a sell signal from the short-term Moving Average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock. On further gains, the stock will meet resistance from the short-term Moving Average at approximately **\$31.88**. On a fall, the stock will find some support from the long-term average at approximately **\$31.71**. A break-up through the short-term average will send a buy signal, whereas a breakdown through the long-term average will send a sell signal. Volume is rising along with the price. This is considered to be a good technical signal. Some negative signals were issued as well, and these may have some influence on the near short-term development. A sell signal was issued from a pivot top point on **Thursday, March 28, 2024**, and so far it has fallen -10.39%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD).

On the downside, the stock finds support just below today's level from accumulated volume at \$28.86 and \$27.11. On the upside the stock meets some resistance just above today's level from accumulated volume at \$31.86, \$33.50 and \$33.69.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved \$1.80 between high and low, or 5.98%. For the last week, the stock has had daily average volatility of 5.32%.

Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for **Tandem Diabetes Care** stock to perform well in the short-term. We have upgraded our analysis conclusion for this stock since the last evaluation from a Sell to a Buy candidate.

Risk: Medium

**Evaluation: Buy Candidate**